NCT03007329 - Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

November 26, 2019

Study Completion Date

January 16, 2020

Conditions

Steatosis, LiverType2 Diabetes

Interventions

DRUG

Exenatide

Exenatide will be combined with Dapagliflozin

DRUG

Exenatide matching Placebo

Exenatide matching Placebo will be combined with Dapagliflozin

DRUG

Dapagliflozin

Dapagliflozin, in both arms

Trial Locations (1)

Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III, Vienna